# Prevalence of thyroid autoimmunity among chronic urticaria patients in comparison to healthy controls

### **Thesis**

Submitted for partial fulfillment of Master degree in **Immunology and Internal Medicine** 

Presented by:

Manar Farouk Mohamed Ali Aglan

M.B.B.Ch.

(Ain Shams university)

Supervised by:

# Prof. Dr. Ashraf Mahmoud Okba

Professor of Immunology and Internal Medicine Faculty of Medicine, Ain Shams University

# Dr. Dina Sayed Sheha

Lecturer of Immunology and Internal Medicine Faculty of Medicine, Ain Shams University

# Dr. Asmaa Saber Moustafa

Lecturer of Immunology and Internal Medicine Faculty of Medicine, Ain Shams University

> Faculty of Medicine Ain Shams University 2013

# قَالُوا سُبْحَانَكَ لاَ عِلْمَ لَنَا إِلاَّ مَا عَلَّمْ تَنَا إِلاَّ مَا عَلَّمْتَنَا إِنَّكَ أَنتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

سورة البقرة آية (32)



I humbly submit my sincere gratitude to Almighty Allah (God), our creator, who was never too busy to answer a prayer, who has guided me to every success I have had throughout all my life.

My deepest and special gratitude is offered to **Prof. Dr. Ashraf Mahmoud Okba**, Professor of Immunology and Internal medicine, Faculty of medicine, Ain Shams University, for his constructive criticism, generous help, encouragement and support. It was an honor to work under his direct supervision.

Sincere appreciation is extended to **Dr. Dina Sayed Sheha**, Lecturer of Immunology and Internal medicine, Faculty of medicine, Ain Shams University, who sacrificed much of her valuable time to assist me by giving guidance and personal assistance.

Special recognition and special thanks to **Dr. Asmaa Saber Moustafa**, Lecturer of Immunology and Internal medicine, Ain
Shams University, for her kind supervision, indispensable advice
and great help in this work.

I am deeply grateful to my family, my Friends and colleagues who directed and encouraged me during the preparation of this work.

And lastly, special thanks to all those who had assisted me in a way or other during the preparation of the work.



Manar Farouk Mohamed Ali Aglan

# **List of Contents**

|                       | Page |
|-----------------------|------|
| Acknowledgment        |      |
| List of Abbreviations | i    |

| List of Figures                               |     |
|---|-----|
| List of Tables                                |     |
| Introduction and Aim of the Work              | 1   |
| Review of Literature                          | 4   |
| Chapter 1 : Allergy                           | 4   |
| Chapter 2 : Urticaria                         | 9   |
| Chapter 3 : Chronic Auto Immune Urticaria     | 25  |
| Chapter 4: Thyroid Diseases and Chronic       |     |
| autoimmune urticaria                          | 37  |
| Chapter 5 : Autologous serum skin test (ASST) | 50  |
| Subjects and methods                          | 54  |
| Results                                       | 66  |
| Discussion                                    | 91  |
| Summary and Conclusion                        | 101 |
| Recommendations                               | 104 |
| References                                    | 105 |
| Arabic Summary                                |     |
|   |     |

# List of Abbreviations

ARBS Angiotensin II Receptor Blockers

ACEI Angiotensin-converting-enzyme inhibitor

AMA ABs
Anti TgAB
Anti TgAB
Anti thyroglobulin anti bodies
Anti-TPO antibody
Anti thyroperoxidase antibodies

APC Antigen-presenting cells ANA Anti-nuclear antibody

AITD Autoimmune Thyroid Disease
ASST Autologous skin sensitivity test

C1-INH C1-esterase inhibitor

CAU Chronic auto immune urticaria
CIU Chronic Idiopathic Urticaria

CU Chronic Urticaria
CBC Complete blood count
Diabetes mellitus
DIT Diiodo-tyrosines

ELISA Enzyme linked immunosorbant assay

ESR Erythrocyte sedimentation rate

FceRI. Fc epsilon RI

FC receptors (Fragment, crystallizable) region

FT4 Free T4

H-pylori Helicobacter pylori

HBsAg
HCV Ab
Hepatitis B surface antibody
Hepatitis C virus antibody
HaE
Hereditary angioedema
High endothelial venules

HPT Hypothalamic/pituitary/thyroid

HTN Hypertension

IGE Immunoglobulin E

IGF-I Insulin-like growth factor I

IFN-γ Interferon-gamma

ILs Interleukins

KFT Kidney function test Late-phase reaction

# List of Abbreviations (Cont.)

LTC4 Leukotriene C4
LFT Liver function test
MIT Monoiodo-tyrosines

NSAIDS Nonsteroidalanti-inflammatorydrugs

RAST Radio Allegro Sorbent Test SLE Systemic lupus erythematosus

TMB Tetramethylbenzidine Thyroid autoantibodies

Tg Thyroid gland Thyroid hormones

TMA Thyroid antimicrosomal AB TPD Thyroid antiperoxidase

TSH Thyroid stimulating hormone

TSI Thyroid stimulating immunoglobulin

TRH Thyrotropin releasing hormone
TBG Thyroxine binding globulin
UAS-7 Urticaria activity score -7

# **List of Figures**

| Fig. | Legend  | Page |
|------|---|------|
| 1    | Early immune response   | 6    |
| 2    | Urticaria developed after bites   | 10   |
| 3    | Urticaria associated with a drug  | 10   |
| 4    | Classification of urticaria   | 11   |
| 5    | Type I immune reactions   | 15   |
| 6    | Mechanism of chronic autoimmune mediated urticaria                              | 25   |
| 7    | Mechanism of chronic autoimmune mediated urticaria                              | 27   |
| 8    | Activation of cutaneous mast cells by IgG antibody directed to the IgE receptor | 30   |
| 9    | Approach to the patient with urticaria  | 33   |
| 10   | Autologous serum-plasma skin test   | 34   |
| 11   | Autologous serum-plasma skin test from our clinic                               | 51   |
| 12   | The Wintrobe sedimentation rack   | 57   |
| 13   | ESR technique   | 58   |
| 14   | Skin prick test on the forearm  | 63   |
| 15   | Gender distribution among Healthy control and group A                           | 70   |
| 16   | Frequency of TgAB positivity among group A                                      | 73   |
| 17   | Frequency of AMA positivity among group A                                       | 73   |
| 18   | Frequency of TgAB positivity among group B                                      | 73   |
| 19   | Frequency of AMA positivity among group B                                       | 75   |
| 20   | Frequency of TgAB positivity among healthy control group                        | 77   |
| 21   | Frequency of AMA positivity among healthy control group                         | 77   |
| 22   | Mean TSH difference between healthy control and group A                         | 79   |
| 23   | Frequency of TgAB+ve and AMA+ve cases among (Group A) and healthy control       | 79   |

# $List\ of\ Figures\ ({\tt Cont.})$

| Fig. | Legend  | Page |
|------|---|------|
| 24   | Mean total IgE difference between Healthy control and ASST-ve group B           | 81   |
| 25   | Mean T3 difference between group A and group B                                  | 82   |
| 26   | Frequency of TgAB+ve and AMA+ve cases among Group A and group B                 | 83   |
| 27   | Comparison between TgAB+ve and TgAB-ve cases as regards to AMA positive results | 85   |
| 28   | Comparison between AMA+ve and AMA-ve cases as regards to TgAB positive results  | 88   |
| 29   | Mean TSH difference between healthy control, group A & group B                  | 89   |
| 30   | Frequency of TgAB & AMA positivity among healthy control, group A & B           | 90   |

# **List of Tables**

| Table | Legend  | page |
|-------|---|------|
| 1     | Relevant investigations of urticaria  | 19   |
| 2     | Thyroid antibodies  | 46   |
| 3     | Redness score of ASST   | 65   |
| 4     | Demographic distribution of group A   | 67   |
| 5     | Demographic distribution of group B   | 68   |
| 6     | Demographic distribution of healthy control                                 | 68   |
| 7     | Comparison between ASST +ve case and  | 69   |
|       | healthy control as regards to demographic distribution                      |      |
| 8     | Comparison between ASST -ve group B and                                     | 70   |
|       | Healthy control as regards to demographic distribution                      |      |
| 9     | Comparison between ASST +ve case group B                                    | 71   |
|       | and ASST –ve case group A as regards to                                     |      |
|       | demographic distribution  |      |
| 10    | Laboratory investigations of group A  | 72   |
| 11    | Laboratory investigations of group B  | 74   |
| 12    | Laboratory investigations of healthy control                                | 76   |
| 13    | Comparison between Laboratory investigations of group A and Healthy control | 78   |
| 14    | Comparison between laboratory investigations                                | 80   |
| 14    | of the ASST –ve group B and the Healthy                                     | 80   |
|       | control   |      |
| 15    | Comparison between group A and group B                                      | 82   |
| 16    | Comparison between TgAB +ve and -ve cases                                   | 84   |
|       | group A as regards to demographic distribution                              |      |
| 17    | Comparison between TgAB +ve and -ve cases                                   | 85   |
|       | group A as regards to Laboratory investigations                             |      |
| 18    | Comparison between AMA +ve and AMA-ve                                       | 86   |
|       | cases group A as regards to demographic                                     |      |
|       | distribution  |      |

# List of Tables (Cont.)

| Table | Legend                                      | page |
|-------|---|------|
| 19    | Comparison between AMA+ve and AMA-ve        | 87   |
|       | cases group A as regards to Laboratory      |      |
|       | investigations                              |      |
| 20    | Comparison between healthy control, group A | 88   |
|       | & group B as regards IgE, T3, T4 & TSH      |      |
| 21    | Comparison between healthy control, group A | 89   |
|       | & group B as regard thyroid Abs             |      |
| 22    | Studies showing prevalence of thyroid       | 90   |
|       | antibodies                                  |      |

# Introduction

"Urticaria" is defined as a transient edematous papules, plaque with itching. It is a clinical reaction pattern triggered by many factors causing the liberation of vasoactive substances such as histamine, prostaglandins and kinins. Urticaria is classified according to its duration into acute (<6 weeks duration) and chronic (>6 weeks duration) (*Shankar et al.*, 2010).

Chronic urticaria (CU) is a common skin disorder, affecting 0.1% -1% of the general population. It is characterized by recurrent and transitory (<24 hours) pruritic erythematous wheals that present at least twice weekly for at least 6 weeks (*Abd El-Azim and Abd El-Azim*, 2011).

Leznoff et al. (1983), suggested an autoimmune basis for the urticaria. This was after the observation that there was an association between thyroid disease and chronic idiopathic urticaria (CIU).

After that *Gruber et al.* (1988), detected functional anti-IgE antibodies and proposed that these could be the cause of urticarial wheals. It is now well-established that about 30-50% patients with CU have circulating functional auto antibodies against the high-affinity IgE receptor (FCeRIa) or against IgE (Sachdeva et al., 2011).

There is a growing evidence that some cases of chronic idiopathic urticaria (CIU) are associated with many auto immune diseases as thyroid autoimmunity. The frequency of thyroid antibodies in patients with CIU was 30%, which is higher than that previously reported (*Najib et al.*, 2009).

The autologous serum skin test has proved to be a useful screening in vivo test for autoimmune urticaria (*Greaves*, 2002).

# Introduction and Aim of The Work

Patients with a positive ASST are more likely to be, associated with HLADR4, to have autoimmune thyroid disease, a more prolonged disease course and may be less responsive to H1-antihistamine treatment than those with a negative ASST (*Konstantinou et al.*, 2009).

.....

# **Aim of The Work**

The study aims at detecting prevalence of markers of thyroid autoimmunity(thyroid auto antibodies with or without underlying abnormal thyroid functions) among a cohort of ASST positive patients with CU in comparison to ASST negative CU patients as controls, and its correlation with the severity of symptoms.

3

# **Allergy**

### i. Definition:

An **allergy** is a hypersensitivity disorder of the immune system. Allergic reactions occur when a person's immune system reacts to normally harmless substances in the environment. A substance that causes a reaction is called an allergen. These reactions are acquired, predictable, and rapid (*Lwloar et al.*, 1995).

Allergy is one of four forms of hypersensitivity and is formally called *type I* (or *immediate*) hypersensitivity. Allergic reactions are distinctive because of excessive activation of certain white blood cells called mast cells and basophils by a type of antibody called Immunoglobulin E (IgE). This reaction results in an inflammatory response which can range from uncomfortable to dangerous response (*Lwloar et al.*, 1995).

Mild allergies like hay fever are very common in the human population and cause symptoms such as red eyes, itchiness, and runny nose (*Busse*, 2000), eczema, hives, or an asthma attack (*Schoenwetter*, 2000).

Allergies can play a major role in conditions such as asthma. In some people, severe allergies to environmental or dietary allergens or to medication may result in life-threatening reactions called anaphylaxis. Food allergies, and reactions to the venom of stinging insects such as wasps and bees are often associated with these severe reactions (*Kay*, 2000).

A variety of tests exist to diagnose allergic conditions. These include placing possible allergens on the skin and looking for a reaction such as swelling (skin prick test). Blood tests can also be done to look for an allergen-specific IgE (RAST), Total IgE testing, Eosinophil counts (*Tas*, 2009).

# ii. Pathophysiology:

### In early phase response:

A type I hypersensitivity reaction against an allergen encountered for the first time and presented by a professional Antigen-Presenting Cell causes a response in a type of immune cell called a T<sub>H</sub>2 lymphocyte, which belongs to a subset of T cells that produce a cytokine called interleukin-4 (IL-4). These T<sub>H</sub>2 cells interact with other lymphocytes called B cells, whose role is production of antibodies, known as IgE. Secreted IgE circulates in the blood and binds to an IgE-specific receptor on the surface of other kinds of immune cells called mast cells and basophils, which are both involved in the acute inflammatory response. The IgE-coated cells, at this stage are sensitized to the allergen (*Xystrakis et al.*, 2006).

If later exposure to the same allergen occurs, the allergen can bind to the IgE molecules held on the surface of the mast cells or basophils. Cross-linking of the IgE and Fc receptors occurs when more than one IgE-receptor complex interacts with the same allergenic molecule, and activates the sensitized cell. Activated mast cells and basophils undergo a process called degranulation, during which they release other inflammatory chemical histamine and (cytokines, interleukins, leukotrienes, and prostaglandins) from their granules into the surrounding tissue causing several systemic effects, such as vasodilation, mucous secretion, nerve stimulation, and smooth muscle contraction. This results in rhinorrhea, itchiness, dyspnea, and anaphylaxis (Brunnée et al., 1997).

# Late-phase response:

After the chemical mediators of the acute response subside, late phase responses can often occur. This is due to the migration of other leukocytes such as neutrophils,